Welcome to our Investor Relations web page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.
Race Oncology is a specialty pharmaceutical company focused on rediscovering or repurposing overlooked drugs that can deliver early commercial milestones. The Company’s business model is to pursue later stage drug assets with an opportunity to quickly bring them to market. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
An article titled: “The Rediscovery of Bisantrene: A Review of the Literature” was recently published in the International Journal of Cancer Research & Therapy. The author of the article is Dr John Rothman, Chief Scientific Officer of Race Oncology. The article can be viewed online here.